Skip to content
Back to meeting Original
Annals of Oncology路 @Annals_Oncology 路 X路路 2 days agoScore70

ARTEMIS-011

Body

馃摙 #ESMO26 concomitant paper - Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.
馃敆https://shorturl.at/vwCM2

110 views 路 2 likes 路 1 repost 路 0 replies

Source: Annals of Oncology 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.